Should I buy, hold, or sell ABVC stock right now?

ABVC BioPharma Inc. (ABVC) currently earns a Roarable Rating of E (Strong Sell — SELL) with 32/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is ABVC's 12-month price target and RQD AI Jury consensus?

ABVC's 12-month base price target is $0.87 (range $0.68 to $3.21), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Stock Ratings / Health Care / ABVC

BCTX (40) CPHI (35) BYSI (37) CELU (26) ⌘ Pro Terminal →

ABVC BioPharma Inc. (ABVC) — RQD Stock Rating Cockpit

$0.98 -1.99% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.97

ABVC BioPharma Inc. (ABVC) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $26.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ABVC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ABVC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, ABVC BioPharma Inc. (NASDAQ: ABVC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $0.98 (-1.99% 1D, market cap $26.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ABVC ranks #733 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ABVC compare to BCTX and CPHI in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABVC carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCTX (BriaCell Therapeutics Corp.) holds a D- grade (40/100 RQD, P/E N/A, ROIC —, cap $26.5M) and CPHI (China Pharma Holdings Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -11.4%, cap $26.9M). Among the 5-stock peer group, ABVC leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ABVC?

▼

Per ABVC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001173313), ABVC BioPharma Inc. generated $20.0M in revenue (+3829.3% YoY), -$7.9M in net income, and -$3.0M in free cash flow against $21.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.97 (-0.55%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABVC)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY ABVC SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.98-5.1% Next Q

Q2 (-2Q)

Grade E$0.93+12.9% Next Q

Q3 (-1Q)

Grade E$1.05-6.7% Next Q

Current

Grade E$0.98-9.2% Hist 90D α

Trajectory: E (24) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ABVC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ABVC currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.00) and Max Pain ($1.03) forces dealer call-delta covering toward $3.21.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABVC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ABVC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

48.230 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

1 / 99-Pt Accounting

52-WEEK LASER RANGE11% OF RANGE

L: $1$0.98H: $3

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 9 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on ABVC

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 42.0% gross margin and -10.76% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (25)

9/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like ABVC

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABVC)

✓Walkthrough of ABVC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ABVC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.67%⚡ TESTING RESISTANCE

2026-11-03O $1.04H $1.04L $0.98C $0.98VOL 20.2K

RES: $1.07SUP: $0.94SMA50: $1.00SMA200: $1.25

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ABVC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ABVC Butterfly Map → + Track ABVC →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +3829.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ABVC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ABVC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ABVC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABVC)

Health Care Rank #733 of 1015 ⚔️ BCTX vs ABVC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ABVC vs. BCTX, CPHI, BYSI, CELU)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, ABVC BioPharma Inc. (ABVC) ranks #733 by composite RQD confidence (32/100, grade E) and #809 by equity capitalization ($26.7M). Within this direct 5-issuer industry benchmark cohort, ABVC leads on earnings valuation at N/A trailing P/E, while CPHI leads on capital efficiency and profitability with -11.4% ROIC and -3.2% gross margin. BCTX currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with ABVC at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ABVC ACTIVE ABVC BioPharma Inc.	E	32/100	—	—	-35.0%	-1.99%	$26.7M	Benchmark Subject
BCTX BriaCell Therapeutics Corp.	D-	40/100	—	—	—	+1.65%	$26.5M	/bctx-vs-abvc →
CPHI China Pharma Holdings Inc.	D-	35/100	—	-3.2%	-11.4%	-2.98%	$26.9M	/cphi-vs-abvc →
BYSI BeyondSpring Inc.	D-	37/100	—	—	-35.0%	+25.18%	$26.5M	/bysi-vs-abvc →
CELU Celularity Inc. (Class A)	E	26/100	—	24.4%	-35.0%	+0.30%	$26.0M	/celu-vs-abvc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001173313 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ABVC BioPharma Inc. (ABVC) reported GAAP revenue of $20.0M (+3829.3% vs. FY2024 revenue of $509.6K , and +13036.2% cumulative change since FY2023) , GAAP net income of -$7.9M, operating cash flow of -$3.0M, and free cash flow of -$3.0M (-65.1% YoY). On the balance sheet, ABVC closed FY2025 with $21.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$20.0M	-$7.9M	-$3.0M	-$3.0M	$21.1M	—
FY2024 (FY)	2024-12-31	$509.6K	-$4.9M	-$1.8M	-$1.8M	$7.5M	—
FY2023 (FY)	2023-12-31	$152.4K	-$7.8M	-$4.2M	-$4.2M	—	—

3. ABVC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ABVC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ABVC compare to BCTX and CPHI in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ABVC?

Where is ABVC trading relative to its 50-day, 200-day, and 52-week technical levels?

ABVC last traded at $0.98 (-1.99% on volume of 30,178 shares), positioning the stock -2.00% below its 50-day simple moving average ($1.00) and -21.60% below its 200-day simple moving average ($1.25). Across its 52-week range of $0.71 to $3.06, ABVC sits at the 11.5% percentile with a 14-day RSI of 48.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.10).

Direct Sub-Reports: ABVC RQD Cockpit ABVC 12M Forecast ABVC Earnings & Move ABVC Dividends & DRIP ABVC Insiders & 13F ABVC Whale Options ABVC Profit Sankey ABVC News & Why

ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ SEC XBRL & RQD VERIFIED

ABVC — ABVC BioPharma Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

ABVC BioPharma Inc. (ABVC) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.98 (-1.99% 1D, market capitalization $26.7M).

Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -10.76%.
Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

ABVC BioPharma Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It is listed on NASDAQ.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), ABVC BioPharma Inc. (ABVC) reported $20.0M in annual revenue (up from $509.6K in FY2024, +3829.3% YoY) and -$7.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($152.4K revenue, -$7.8M net income) through FY2025, ABVC scaled operating cash flow to -$3.0M and free cash flow to -$3.0M, backed by $21.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -10.76% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $0.71 – $3.06 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ABVC carries a macro regime beta of 1.00 and gross margin of —.

Key Question #1: Can ABVC sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $20.0M and free cash flow of -$3.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is ABVC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ABVC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ABVC BioPharma Inc. (ABVC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ABVC Debate Forum (3) ↓

🟡 MARKET WIRE Moomoo • 22h ago

ABVC BioPharma(ABVC) Stock Options Chain | Quotes & News

Moomoo report covering ABVC BioPharma Inc. (ABVC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo! Finance Canada • 1d ago

WallachBeth Capital Announces ABVC BioPharma Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million

Yahoo! Finance Canada report covering ABVC BioPharma Inc. (ABVC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com UK • 1d ago

Form 8K ABVC Biopharma Inc For: 2 November By Investing.com

Investing.com UK report covering ABVC BioPharma Inc. (ABVC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com India • 1d ago

ABVC BioPharma raises $3.39 million via convertible notes By Investing.com

Investing.com India report covering ABVC BioPharma Inc. (ABVC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TipRanks • 1d ago

ABVC BioPharma Closes $4.11 Million Convertible Note Financing

TipRanks report covering ABVC BioPharma Inc. (ABVC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH WallachBeth Capital LLC/ • 22h ago

/C O R R E C T I O N

WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC), has closed a private placement of origina

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 23h ago

ABVC BioPharma Announces Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million

SILICON VALLEY, CA - November 2, 2026 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC), today announced the closing of a private placement of original issue discount senior convertible promi

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 133d ago

ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders

SILICON VALLEY, CA - June 23, 2026 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("ABVC" or the "Company"), a clinical-stage biopharmaceutical company focused on botanical-derived therapeutics and commercial ingre

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ABVC Bull vs. Bear Conversation Board — What's Your Call at $0.98?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABVC 🐻 33% BEARISH CONVICTION

BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $1.16 (+16.0%)

📌 Pinned Debate

The balance-sheet pillar scores 10 of 20, with Altman Z at 2.5 and Debt/Equity at 0.5, the strongest reading in the RQD rating.

Picked up a starter position in ABVC in my $100K Virtual Cash book at $1.00. The balance-sheet pillar scores 10 of 20, with Altman Z at 2.5 and Debt/Equity at 0.5, the strongest reading in the RQD rating.. Trading inside a $0.71–$3.06 52-week range with -10.76% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

RetailWhale_TX 🐂 BULL

Both sides have a point here — ABVC's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $0.86 (-14.0%)

Spot @ $1.00

Operating and net income are negative in every reported period, with FY 2025 net loss of -$7.9M against cash of $0.7M and an RQD score

Careful chasing ABVC at $1.00. Operating and net income are negative in every reported period, with FY 2025 net loss of -$7.9M against cash of $0.7M and an RQD score of 32.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.86 on multiple compression.